Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$166.1MCash on Hand
20.6mo Cash Runway
Follow IVA by emailGet an email when IVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IVA, unsubscribe in one click. Privacy
📣 What IVA Says Is Next
fourth quarter of this year · Lanifibranor: “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.”
Company press release, Oct 6, 2026 · SEC filing
first half of 2027 · “If the NATiV3 topline results are favorable, the Company anticipates regulatory submission in the first half of 2027 and is preparing for a potential U.S. launch of lanifibranor in 2028, subject to U.S. Food and Drug Administration (“FDA”) approval.”
Company press release, Sep 28, 2026 · SEC filing
fourth quarter of 2026 · “Inventiva expects to report topline results from the Phase 3 clinical trial NATiV3 in the fourth quarter of 2026.”
Company press release, Sep 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 6, 2026 ·
Inventiva will present three abstracts at AASLD The Liver Meeting 2026 (Nov 5-9, Denver) on lanifibranor's pan-PPAR activity, including preclinical and Phase 2b data on liver sinusoidal endothelial cells. Topline Phase 3 NATiV3 results are expected in Q4 2026. Form 6-K · SEC filing · Press release
Sep 28, 2026 ·
Earnings Inventiva filed its interim financial report, first-half 2026 press release and corporate presentation, all dated September 28, 2026. The filing text itself contains no figures, so the financial results are not stated here. Form 6-K · SEC filing · Press release
Sep 3, 2026 ·
Clinical trial Inventiva said the last patient completed the final 72-week visit in the NATiV3 Phase 3 trial of lanifibranor in MASH, with 1,009 patients in the main cohort and 410 in the exploratory cohort. Topline results are expected in Q4 2026. Form 6-K · SEC filing · Press release
Sep 1, 2026 ·
Leadership Appointed Chris Benecchi as Chief Operating Officer to lead operational readiness ahead of the NATiV3 Phase 3 topline results for lanifibranor in MASH, expected in Q4 2026, and potential U.S. launch anticipated in 2028. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2026 · Phase 3 · Active Trial · A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not IVA's own candidates): Empagliflozin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IVA holds $166.1M in cash and short-term investments and burns about $24.1M/quarter from operations,
an estimated runway of 20.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:28 · Moderate
Cash runway 21 months +8
Shelf registration (F-3ASR, Jun 2026) +10
Share count +102% in a year +20
Raised after last reported balance sheet (Jun 2026) -10
Share count 193,236,978 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IVA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IVA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.